Form MA-I/A Kaufman, Hall & Associat
- Wall Street surges to all-time closing high on earnings, economic revival
- Was Intel's (INTC) Second Quarter a Speedbump or Inflection?
- Twitter (TWTR) Gains After Beating Q2 Estimates, Analysts Raise PTs as Brand Recovery Accelerates
- U.S. dollar on track for second week of gains; Fed meeting in focus
- Snap (SNAP) Surges 17% After Smashing Q2 Views Across the Board to Yield a Dozen Price Target Hikes
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
MA-I/A 0001623387 XXXXXXXX Kenneth McManus 973-618-9508 firstname.lastname@example.org email@example.com Y N Ilan Simcha Weissberg N 1 0001623387 Kaufman, Hall & Associates, LLC 10-23-2016 N 867-01238 LOCATED SUPERVISED 10-23-2016 10 S WACKER DR SUITE 3375 CHICAGO IL 60606 10-2016 Kaufman, Hall & Associates LLC CHICAGO IL 60606 Y N Research Analyst 03-2014 10-2016 Weissberg and Associates, Ltd. Chicago IL 60605 N N Paralegal 09-2008 06-2014 DePaul University Chicago IL 60091 N N Student 05-2008 09-2008 Unemployed Chicago IL 60091 N N Unemployed 01-2008 05-2008 United States Marine Corps Bogota F8 00000 N N Sergeant of Marines N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 06-23-2021 Kimberly McManus President, Alternative Regulatory Solutions LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Prospective Study Shows Significant Reduction In Reports Of Postoperative Halos From Patients Treated With TearScience LipiFlow Treatment Prior To Bilateral Cataract Surgery
- Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
- Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!